Table I.

Baseline demographics of patients receiving ulinastatin treatment.

Patient no.	Sex	Age, years	Principle symptoms	Comorbidity	Disease severity	Days of admission from symptom onset	Days of initiation of ulinastatin treatment fromhospital admission
1	M	73	Fever, dyspnea, headache	Hypertension	Severe	6	1
2	F	72	Fever, cough	Hypertension, DM, CCVD	Severe	2	10
3	M	74	Fever	COPD	Moderate	8	8
4	F	87	None	Hypertension, dementia	Moderate	2	0
5	M	55	Cough, muscle ache, dyspnea, chest distress	Hypertension	Severe	9	0
6	M	72	Cough, dyspnea	Hypertension, CCVD	Severe	1	2
7	M	77	Fever, cough, dyspnea	Hypertension, DM	Severe	4	6
8	M	81	Fever, chest distress, fatigue	Hypertension	Severe	21	6
9	M	57	Fever, cough, chest distress, dyspnea	None	Severe	24	0
10	M	56	Dizziness, fatigue	None	Severe	18	1
11	M	65	Fever, fatigue, anorexia	Hypertension	Severe	19	0
12	M	48	Fever	None	Severe	6	0

M, male; F, female; DM, diabetes mellitus; CCVD, cardio-cerebrovascular disease; COPD, chronic obstructive pulmonary disease.